Actively Recruiting
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Led by Accutar Biotechnology Inc · Updated on 2025-10-02
60
Participants Needed
9
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
CONDITIONS
Official Title
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult male and female patients at least 18 years old at the time of consent
- Histologically confirmed relapsed or refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, non-GCB Diffuse Large B-cell Lymphoma, Marginal Zone Lymphoma, or Waldenström Macroglobulinemia
- Received at least two prior systemic therapies or have no other therapies likely to provide significant clinical benefit according to the investigator or are not suitable for standard therapies due to intolerance or patient choice
You will not qualify if you...
- Treatment with small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, up to 14 days)
- Systemic chemotherapy within 14 days
- Radiation therapy within 14 days
- Biologic antibody treatments within 28 days
- Radioimmunoconjugates or toxin conjugates within 12 weeks
- Prior CAR T-cell therapy within 3 months; for DLBCL patients, no prior CAR T therapy allowed
- Autologous or allogenic stem cell transplant within 100 days, with no ongoing graft-versus-host disease or treatment for it
- History of central nervous system lymphoma or leukemia in remission less than 2 years
- Active bleeding within 2 months before study entry or increased bleeding risk as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
Actively Recruiting
2
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
3
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
4
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
5
The Ohio State University - The James Cancer Hospital and Solove Research Institute
Columbus, Ohio, United States, 43210
Actively Recruiting
6
Oregon Health & Science University
Portland, Oregon, United States, 97239
Actively Recruiting
7
Tennessee Oncology
Nashville, Tennessee, United States, 37302
Withdrawn
8
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
9
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
A
Accutar Biotechnology
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here